Modeling estrogen receptor-positive breast cancers in mice: is it the best we can do?
The continuous supplementation of mice with supraphysiological doses of estrogen  for the growth of estrogen receptor-positive breast cancers has been linked to toxicity in the host and perturbation of cancer cells' function that can misguide preclinical studies. Thus, alternative experimental models with circulating levels of estrogens higher than those of mice may represent more suitable hosts to model estrogen receptor-positive breast cancers.
Department of PathologyMicrobiology and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, USA.
Ioulia
I
Chatzistamou
Department of Drug Discovery and Biomedical SciencesUniversity of South Carolina, Columbia, South Carolina, USA Peromyscus Genetic Stock CenterOffice of Research, University of South Carolina, Columbia, South Carolina, USA Department of BiochemistryUniversity of Athens Medical School, Athens, Greece kiarish@sccp.sc.edu.
Hippokratis
H
Kiaris
D000818:Animals; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004958:Estradiol / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology / Q000502:physiology; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology*; D051379:Mice; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism* / Q000502:physiology
D004967:Estrogens; D011960:Receptors, Estrogen; D004958:Estradiol
breast cancer; cancer model; estrogen receptor; estrogen supplementation